---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013236"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:41:38.908470+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics Q4 net loss $4.1M; FY net loss $25.6M; CLD-401 IND on track for end-2026

## Summary
- Q4 net loss $4.1M ($0.57/sh); FY net loss $25.6M ($5.95/sh) vs $23.8M ($35.70/sh) in 2024.
- Cash and restricted cash $5.8M at Dec 31, 2025, down from $9.8M a year ago; raised $6.5M in offering/ATM.
- Partnered with Avance Clinical to initiate CLD-401 first-in-human trial in Australia; plans to file IND by end-2026.
- Presented in situ T-cell engager data at AACR-IO; partnered with Matica Bio for GMP manufacturing of CLD-401.

## SEC filing metadata
- accession: 0001493152-26-013236
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/0001493152-26-013236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013236
- JSON: https://secwatch.observer/filing/0001493152-26-013236.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013236.txt

## Key facts
- Earnings Releases
  Calidi Biotherapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $25.6 million, or $5.95 per share, for the year ended December 31, 2025, EPS $5.95 per share.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Net income: $25.6 million, or $5.95 per share, for the year ended December 31, 2025
  - EPS: $5.95 per share
  - Result: reported results
  source text: The company reported a net loss attributable to common stockholders of $4.1 million, or $0.57 per share, for the three months ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/0001493152-26-013236-index.htm
- Earnings Releases
  Calidi Biotherapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $25.6 million, or $5.95 per share, for the year ended December 31, 2025, EPS $5.95 per share.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Net income: $25.6 million, or $5.95 per share, for the year ended December 31, 2025
  - EPS: $5.95 per share
  - Result: reported results
  source text: The company reported a net loss attributable to common stockholders of $25.6 million, or $5.95 per share, for the year ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/0001493152-26-013236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.